Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL)

Main Article Content

Jonathan I Silverberg
Weily Soong
Benjamin Lockshin
Abhijit Gadkari
Zhen Chen
Ashish Bansal

Keywords

Atopic Dermatitis, Biologics, Dupilimab, Mental Health, Anxiety, Depression

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

2. Yu SH, Silverberg JI. J Invest Dermatol. 2015;135:3183-6.

3. Eckert L, et al. J Am Acad Dermatol. 2017;77:274-9.

4. Silverberg JI, et al. J Invest Dermatol. 2019;139:1388-91.

5. Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52.

6. Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153-8.

7. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35-50.

8. Gandhi NA, et al. Expert Rev Clin Immunol. 2017;13:425-37.

9. Simpson EL, et al. N Engl J Med. 2016;375:2335-48.

10. Simpson EL, et al. JAMA Derm. 2019; Nov 6 [Epub ahead of print]. doi: https://doi.org/10.1001/jamadermatol.2019.3336.

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.47

Article Details

How to Cite
[1]
Silverberg, J.I., Soong, W., Lockshin, B., Gadkari, A., Chen, Z. and Bansal, A. 2020. Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL). SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s48. DOI:https://doi.org/10.25251/skin.4.supp.47.
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 > >>